We analyzed the molecular changes between the control and anthocyanin-treated groups.
Using highly enriched cell populations in combination with multiplatform gene expression profiling studies, a comprehensive analysis of molecular changes between the normal and malignant breast tissue was established.
After 2, 4 and 8 weeks of diet intervention, molecular changes between the low- and high-fat diet were analyzed for each part of the small intestine.
Our analyses provide a better understanding of how preprocessed microarray results reflect RNA levels in diverse biological samples, translating microarray expression value differences into molecular changes between samples, and highlighting tissue-specific noise properties.
Secondary objectives were: (i) to assess drug toxicity; (ii) to determine through pharmacodynamic evaluations whether temsirolimus downregulates mTOR and modulates elements of the PI3K/AKT/mTOR pathway and (iii) to associate pretreatment molecular characteristics, and molecular changes between paired tumour biopsies, with clinical outcome.
Moreover, as the molecular changes between responders and non-responders observed in cancer BMPCs are also reflected in a readily accessible tissue (PBMCs), these data might eventually be translated into novel indicators for selection of MM patients who are more likely to benefit from subsequent melphalan therapy.
Bearing in mind the fact that the spin-crossover transition is accompanied concomitant molecular change, comparison between the characteristic 3D maps of distortion ξ as a function of temperature T and HS fraction n H for different values of pressure p was calculated.
Unlike typical experiments in which excitability is compared between different neurons before and after nerve injury, and where it is impossible to account for all injury-induced molecular changes and between-cell differences, we compared excitability in the same neuron before and after strictly controlled manipulations dictated by our simulation results.
These results suggested that there seemed to be a significant association between the molecular change (overexpression of TrkB) and the morphological change (tumour budding).
These lines of evidence suggest that TrkB may be one of the representative molecules that reveal an association between the molecular change (overexpression of TrkB) and the morphological change (EMT).
By measuring both the likelihood of recovery and the type of mutations underlying recovered function, the authors uncover a relationship between regulatory versus structural mutations and metabolic function, demonstrating a clear and predictable link between molecular change and functional innovation.
